Aspen Neuroscience is a technology company.
Aspen Neuroscience has raised $227.0M across 3 funding rounds.
Aspen Neuroscience has raised $227.0M in total across 3 funding rounds.
Aspen Neuroscience has raised $227.0M in total across 3 funding rounds.
Aspen Neuroscience's investors include Chloe Sladden, CRV, F-Prime Capital Partners, InterWest, Maven Ventures, NextView Ventures, OrbiMed, Otherwise Fund, Tiger Global Management, Tribe Capital, Dafina Toncheva, Y Combinator.
Aspen Neuroscience is a clinical-stage biotechnology company developing personalized autologous cell therapies using patient-derived induced pluripotent stem cells (iPSCs) to address neurodegenerative diseases, starting with Parkinson's disease (PD).[1][2][4][5] Its lead product, ANPD001, is an investigational therapy that replaces lost dopamine-producing neurons by differentiating a patient's skin cells into dopaminergic neuronal precursor cells (DANPCs), eliminating the need for immunosuppressive drugs and enabling scalable manufacturing through automation, machine learning, and genomics.[1][2][4][5] The company serves PD patients with moderate to advanced disease, solving the unmet need for treatments that target the root cause—dopamine neuron loss—rather than just symptoms, with positive early clinical results from its Phase 1/2a trial (NCT06344026).[4][5] Recent momentum includes a $115 million Series C financing in November 2025 to advance ANPD001, facility expansions, and partnerships for automation with Mytos and Cell X Technologies.[1][2][5]
Founded as a San Diego-headquartered private company, Aspen Neuroscience emerged from expertise in stem cell biology, bioinformatics, and regenerative medicine to tackle high unmet needs in neurology.[1][2][3] Key leaders include President and CEO Damien McDevitt, PhD, who emphasizes the team's status as "the best in the world at creating and characterizing iPSCs," and Chief Technology Officer Kim Raineri, driving manufacturing innovations.[1][2] The idea stemmed from combining iPSC technology with AI and genomics for patient-specific therapies, launching pivotal efforts like the 2022 Trial Ready Screening Cohort study for ANPD001 patient enrollment and manufacturing.[3] Early traction built through in-house platforms for cell quality control and clinical advancement, culminating in the ongoing Phase 1/2a trial and 2025 funding to scale operations.[3][5]
Aspen stands out in autologous cell therapy through these key strengths:
Aspen rides the wave of personalized regenerative medicine, leveraging iPSC advancements and AI to make autologous therapies viable at scale amid rising neurodegenerative disease prevalence (e.g., millions affected by PD globally).[1][4] Timing aligns with post-2020 biotech surges in automation and genomics, enabling commercial readiness where prior scalability hurdles stalled progress.[1][2][5] Favorable market forces include investor confidence ($115M Series C), regulatory progress (Phase 1/2a trial), and partnerships accelerating manufacturing—positioning Aspen to influence CNS therapy standards by proving "off-the-shelf" personalization without immune suppression.[3][5] This shifts the ecosystem from symptomatic treatments to restorative ones, inspiring similar platforms in neurology.
Aspen Neuroscience is poised to disrupt PD treatment with ANPD001's commercialization push, fueled by 2025 funding and automation scale-out for broader patient access.[1][5] Upcoming milestones include Phase 1/2a readouts, expanded CNS pipeline trials, and full facility automation, potentially validating autologous models for ALS or other disorders.[4][6] Trends like AI-biotech convergence and digital health integration will amplify growth, evolving Aspen's influence from PD pioneer to regenerative medicine leader—transforming "high unmet need" into scalable hope, as its patient-derived platform restores what was lost.[2][3][4]
Aspen Neuroscience has raised $227.0M across 3 funding rounds. Most recently, it raised $150.0M Series B in May 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2022 | $150.0M Series B | Chloe Sladden, CRV, F-Prime Capital Partners, InterWest, Maven Ventures, NextView Ventures, OrbiMed, Otherwise Fund, Tiger Global Management, Tribe Capital, Dafina Toncheva, Y Combinator, Sam Altman | |
| Mar 1, 2020 | $70.0M Series A | Chloe Sladden, Caffeinated Capital, CRV, Electric Capital, First Round Capital, F-Prime Capital Partners, FPV Fund, General Catalyst, InterWest, Maven Ventures, NextView Ventures, OrbiMed, Otherwise Fund, Susa Ventures, Tiger Global Management, Tribe Capital, Dafina Toncheva, Y Combinator, Greg Brockman, Sam Altman | |
| Dec 1, 2019 | $7.0M Seed | Chloe Sladden, CRV, F-Prime Capital Partners, InterWest, Maven Ventures, NextView Ventures, OrbiMed, Otherwise Fund, Tiger Global Management, Tribe Capital, Dafina Toncheva, Y Combinator, Sam Altman |